Reportlinker.com

Reportlinker.com

June 25, 2008 18:15 ET

Key Challenges and Issues Facing the Chinese Pharmaceutical Outlook 2008-2023

LONDON, UNITED KINGDOM--(Marketwire - June 25, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

Chinese Pharmaceutical Outlook 2008-2023

http://www.reportlinker.com/p090279/Chinese-Pharmaceutical-Outlook-2008-2023.html

This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase, one that will represent a near tripling of total sales over six years. Strong growth will continue well beyond that period, as this report shows and explains.

Over 220 pages full of analysis, graphs, tables and charts - available to you today.

If you are interested in pharmaceutical business in China, you cannot afford to be without this report by visiongain's leading authority on developing pharmaceutical markets.

- The growth of pharmaceutical markets in the developing nations has the potential to offset the slowdown of sales growth in developed markets of North America, Europe and Japan.

- Visiongain predicts that China will exhibit very strong pharma sales growth from 2008-2023. Rapid economic growth and a vast, currently under-served population, will drive that expansion. There will be significant growth in sales of both branded and generic drugs through increasing demand from both public and private healthcare sectors.

Visiongain's Chinese Pharmaceutical Outlook 2008-2023 examines the exciting Chinese pharmaceutical market and industrial sector critically through comprehensive research and analysis. Visiongain applied techniques such as financial forecasting, surveying of key opinion leaders, SWOT analyses and discussion of qualitative factors. Societal, political, economic and commercial issues are covered. The result is a comprehensive market-based report with detailed analysis and informed opinion. This original 220+ page study contains 57 tables and 47 figures. We invite you to examine the table of contents included here.

In particular, visiongain's Chinese Pharmaceutical Outlook 2008-2023 concentrates on the following themes:

- A forecast of the global pharmaceutical market from 2007-2023, with key issues discussed

- Forecasts of sales revenues and growth rates for Chinese pharmaceutical sales from 2007-2023, including key market segments such as Rx, OTC, domestic and foreign sales - all with comprehensive discussion

- Forecasts of sales for leading therapeutic areas and pharma products

- Revenue forecasts for clinical outsourcing in China and relevant discussion

- Revenue forecasts for contract manufacturing in China and relevant discussion

- Drivers and opportunities in the Chinese pharmaceutical sector

- Restraints and threats in that market and industry

- Discussion of key domestic players and important therapeutic areas, including biotechnology, drug development and joint ventures

- Discussion of regulatory, societal and economic issues

Why you should buy this report:

- To receive a comprehensive analysis of the Chinese pharma market and industry from 2007-2023, with both quantitative and qualitative aspects covered

- To discover predicted revenues, sales growth rates and other key metrics for the Chinese pharma sector from 2006-2023

- To determine the forces that influence pharmaceutical sales and related developments in China:

- Competitive characteristics of the market and industry

- Regulatory, technological, societal and political issues

- Drivers and restraints

- Strengths, weaknesses, opportunities and threats

- Expert opinion from China, as obtained by visiongain

- To find out where the Chinese market is heading - both commercially and technologically - including regulatory issues

- To determine key activities of leading companies

- To receive a comprehensive discussion of healthcare provision in China, both public and private.

The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for over 80% of revenues for prescription drugs worldwide. However, there is great concern about the relatively low growth of those established markets in recent years. Consequently, international pharmaceutical companies are striving to raise their profiles in the developing markets of Asia, Latin America and Eastern/Central Europe. Principal amongst those developing markets is the emergent demographic and economic colossus of China.

Growth of the pharmaceutical markets in developing nations will clearly surpass that of the established markets throughout the foreseeable future. That situation will provide one of the greatest opportunities ever available to the international pharmaceutical industry. Those strongly growing national economies drive the reform and broadening of healthcare systems, with increasing sales in all healthcare sectors. Improvements in both the quality and reach of these healthcare provisions will drive the sales of branded and generic drugs in particular. This report will help you to understand those developments and opportunities.

Other benefits to you when you order this report:

- Full searchable report when you buy the company or corporate editions

- Copies can be easily printed for offline reading

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


1 Executive Summary: Chinese Pharmaceutical Outlook 2008-2023 
1.1 Introduction to the Report 
1.2 Research Methods and Content 
1.3 Growth of the Chinese Pharma Market from 2007-2023 
1.4 Cautious Optimism for Chinese Pharma 
2 Introduction: Expansion into Developing Markets - Principally China 
2.1 The World Pharmaceutical Market Continues to Grow, But Faces
 Mounting Challenges 
2.2 The Continuing Success of the Pharmaceutical Industry is Dependent
 upon Important Drivers and Restraints 
2.2.1 Drivers on the Global Pharmaceutical Market 2007-2020 
2.2.2 The Market Will Also Face Considerable Restraints During the
 Foreseeable Future 
2.3 Companies Are Gradually Changing Their Strategic Focus to Overcome 
 Challenges in the Worldwide Market 
2.4 Current Pressures on Industry - Blockbuster Business Model Under
 the Spotlight 
2.5 R&D Strategy is Crucial to Success 
2.6 Greater Regulatory Co-operation is Possible Internationally 
2.7 China Was the Ninth Largest World Pharmaceutical Market in 2006 and
 Is Set to Climb Much Higher in the Rankings in Coming Years 
2.8 North America, Europe and Japan Continue to Dominate the World
 Pharmaceutical Market, But Sales in the Developing Markets Are
 Increasing More Rapidly 
2.9 High Growth in the Developing Pharmaceutical Markets 
2.9.1 Sales Growth in Developing Nations is Outstripping that of the
 Overall World Market and Individual Developed Nations 
2.9.2 Improving Access to Modern Healthcare is a Principal Driver of
 Growth in Developing Nations 
2.10 China is the Most Exciting Prospect for the Pharmaceutical
 Industry at the Moment 
2.10.1 China is a Potential Economic Leader 
2.10.2 China's Total Pharmaceutical Sales are Still Far Behind Those of
 the US and Japan 
2.10.3 Strategies for Market Entry and Consolidation are Vital for
 International Companies 
2.11 WTO Agreements Affect Pharmaceutical Developments in Emerging
 Markets 
2.11.1 The Principal Pharmaceutical Markets Remain the Leading Developed
 Nations But Developing Nations Are Increasingly Tempting 
2.11.2 Background to the WTO and TRIPS 
2.11.3 Lack of Patent Protection Was Rife in Developing Nations Before
 TRIPS 
2.12 Pharmaceutical Companies Will Jostle Vigorously for Position in
 Developing Markets Such as China 
2.12.1 Further International Expansion Will Occur in Pharma from 2008
 to 2020 with China Being a Principal Beneficiary 
2.12.2 Expansion into Developing National Markets Will Help to
 Reinvigorate the Pharmaceutical Industry 
2.13 The Chinese Pharma Industry will be a Principal Beneficiary of
 Globalisation 
3 The Chinese Pharmaceutical Market: its Key Players, Principal
 Therapeutic Areas, Market Drivers and Restraints 
3.1 SWOT Analysis of the Chinese Pharmaceutical Market from 2008-2020
 Shows Both Major Opportunities and Challenges Ahead 
3.2 Growth in National and Personal Prosperity Will Raise Demand for
 Pharmaceutical Products in China 
3.2.1 List of Principal Drivers of the Chinese Pharmaceutical Market
 from 2008-2020 
3.2.2 China Attracts all the Leading Pharma Companies and has a Growing
 Domestic Pharma Industry 
3.2.3 Demographic Changes are a Major Driver of Pharmaceutical Sales
 in China 
3.2.4 Patent Protection and GMP Compliance are also Highly Important
 to Chinese Pharma Market Development 
3.2.5 Rationalisation of the Supply Chain will be a Key Factor 
3.2.6 Modern Pharmaceutical Products Increasing in Usage with 
 Corresponding Decline in Chinese Traditional Medicine 
3.3 Remaining Concerns over the Commercial Environment in China will
 act as a Restraint to Market Growth 
3.3.1 List of Principal Restraints on the Chinese Pharmaceutical
 Market from 2008-2020 
3.3.2 More Effective Regulatory Process and Greater IP Protection Help
 but Progress Required 
3.3.3 Lower Prices Reduce Profit Margins 
3.3.4 New Civil Court for IP Infringement Announced in 2006 
3.3.5 China's Healthcare Provision Requires Major Progress in the Years
 Ahead 
3.3.6 Expanding Healthcare Provision Occurring Gradually Since 1990s 
3.4 Both the Chinese Economy and Its Pharmaceutical Market Benefit from
 Having the World's Largest Population and Labour Force 
3.4.1 World's Largest Population Gives China Vast Potential
 Pharmaceutical Demand in Coming Years 
3.4.2 China has Already become a Major Force in Manufacturing with
 Economic Growth and Important Demographic Changes Occurring at a
 Relentless Pace 
3.4.3 Expansion and Improvement of Education and Training in China
 Will Increasingly Benefit the Pharmaceutical Sector 
3.5 China's Overall Economic Output May Rise to $4 Trillion by 2020 
3.5.1 Output Reached $1.6 Trillion in 2005 
3.5.2 China Rising Fast in International Economic League Tables 
3.5.3 Emphasis on Increasing Personal Income and Consumption 
3.5.4 Increasing Range of Economic Activities in China 
3.5.5 Further Opening of Chinese Economy Will Spur Growth in the
 Years Ahead 
3.6 Greater Expectations for Healthcare and Increasing Resources to
 Pay for Treatments Will Further Drive the Chinese Pharmaceutical Market 
3.6.1 Rising Living Standards Drive Growth of Pharma Industry with both
 Foreign and Domestic Companies Benefiting 
3.6.2 An Expanding Professional Class in China with High Demand for
 Modern Pharmaceuticals 
3.6.3 Marked Disparities Exist Between the Cities and the Rural Areas:
 Relative Poverty Is a Continuing Problem for China, With Implications
 for the Pharmaceutical Market 
3.7 The State Food and Drug Administration is the Main Pharmaceutical
 Regulator in China 
3.7.1 Reorganisation and Consolidation of Pharma Regulation 
3.7.2 The State Food and Drug Administration (SFDA) 
3.7.3 Submission of NDAs and Approval Process in China 
3.7.4 Policy of Requiring Local Clinical Trials an Impediment to the
 Pharma Market in China 
3.7.5 Other Regulatory Functions 
3.7.6 Combined Centre for Drug and Medical Device Approvals by SFDA 
3.7.7 New Regulations for Certifying Imported Bulk Pharmaceuticals 
3.8 Western Medicine is Gradually Superseding Traditional Medications
 in China - Important Progress Being Made but Formidable Challenges Remain
3.8.1 Low Average Per Capita Healthcare Spending at Present but
 Increasingly Strong Market for Modern Prescription Drugs and OTC Products
 in China 
3.8.2 Generic Drugs are a Major Component of the Chinese Pharma Market 
3.8.3 Jiangsu YangZijiang Was the Market Leader in 2006 with
 International Pharmaceutical Leaders Also Performing Well 
3.8.4 Domestic Companies Achieving Impressive Sales Growth in the Chinese
 Market but International Companies Playing Important Role Through
 Subsidiaries 
3.8.5 The Cephalosporin Class Led the Chinese Market in 2006 
3.8.6 Pricing and Reimbursement Issues 
3.8.7 Marketing and Advertisement 
3.9 Pfizer Expanding its Presence in China, Aligning Itself More Closely
 With the Chinese Healthcare Authorities and Other Stakeholders 
3.9.1 Pfizer is Foremost Amongst International Companies Operating in
 China 
3.9.2 Pfizer's Alliances in China are Significant 
3.9.3 Pfizer has a Broad Vision for Competing in the Chinese Market 
3.10 Novartis is also a Leading Pharmaceutical Investor in China 
3.10.1 Novartis Recently Made Significant Inward Investment 
3.10.2 New Plant in Jiangsu Province 
3.11 Novo Nordisk Recently Announced Expansion of Production in China
 - Great Opportunities for Specialist Pharma Companies 
3.11.1 China Will Become a Leading Market for Diabetes Treatments - Novo
 Nordisk is Very Well Placed in that Market 
3.11.2 New Productions Facilities in Tianjing 
3.12 State AIDS Prevention and Treatment Policy in China is Indicative
 of Greater State Involvement in Healthcare with Opportunities for all
 Stakeholders 
3.12.1 Intensive AIDS Prevention and Treatment Programme Announced in
 February 2008 
3.12.2 Chinese Science at Forefront of AIDS/HIV Research in Developing
 World 
3.12.3 Important Opportunities for Both Leading and Specialised Companies
 in the Chinese Anti-Retroviral Market 
3.13 Chronic Diseases Associated with Lifestyle are Increasing Rapidly
 in China 
3.13.1 China Now a Leading Nation for Obesity 
3.13.2 Disease Awareness Campaigns for Chronic "Western" Diseases 
3.13.3 Opportunities for Pharmaceutical Companies to Alleviate These
 Problems 
4 The Chinese Pharmaceutical Market is Expanding Rapidly - Detailed
 Market Forecasts from 2007 to 2020 
4.1 The Chinese Pharmaceutical Market Will Grow Significantly Faster
 than the Global Pharmaceutical Market from 2007-2020 
4.1.1 Chinese Pharmaceutical Market Will Expand to over $30bn by Early
 Next Decade with Strong Growth Continuing to 2020 
4.1.2 Chinese Pharma Market Surpassing Global and Developed Markets in
 Annual Sales Growth - How This Trend Will Continue 
4.1.3 China's World Pharma Market Share Will Continue to Increase from
 2007-2020 
4.1.4 WTO and to TRIPS Issues Remain Important for the Chinese Pharma
 Market 
4.1.5 Pharma Sales Growth Will Remain Strong Despite Inevitable Slowing
 of Chinese Economic Growth and Healthcare Expansion in Future Years 
4.1.6 Investment in Drug Development by Chinese Companies a High Priority
 with State Measures Encouraging Progress 
4.1.7 Inefficiencies and Disparities in Chinese Healthcare Provision
 Currently Hamper Growth but Much Hope for Improvements 
4.2 Prescription Drug Sales Will Continue to Drive the Chinese Market
  from 2007-2020
4.2.1 Sales of Prescription Drugs in China Set to Exceed $50bn by Late
 Next Decade with a CAGR over 15% 
4.2.2 Relative Market Shares for Prescription and OTC Products in China
 from 2007-2020 
4.2.3 OTC Sector Boosted by Trend for Self Medication, Especially for
 Patients Without Health Cover 
4.2.4 Drivers of the Chinese OTC Market Segment 
4.2.5 Multinational Companies and their Subsidiaries Making Good
 Progress in OTC Sector 
4.2.6 Community Pharmacies and Online Sales Driving Growth 
4.2.7 Disease Awareness Campaigns and Increasing Number of Outlets also
 Main Drivers of OTC Segment in China 
4.3 Currently Generic Drugs Dominate the Chinese Prescription Drug Market
 but Original Patented Brands Will Make Inroads 
4.3.1 Strong Growth in both Branded and Generic Sectors from 2007-2020 
4.3.2 Competitive Factors Influencing Sales of Domestic Generics in China 
4.3.3 Large Supply of Generic Drugs by Local Producers Provides
 Domestic Industry with a Major Advantage 
4.3.4 Effects of Generics on Pricing Structures in China 
4.3.5 Tightening of Regulations for Generic Drug Marketing in China 
4.3.6 Gradual Change in Balance of Sales Contributed by Original Branded
 and Generic Products in the Chinese Pharma Market from 2007-2020 
4.3.7 Lack of Bioequivalence Certification for Domestic Generics is a
 Commercial Weakness that Needs to be Rectified 
4.3.8 Economic Forces Protect International Companies from Generic
 Competition in the Chinese Market at Present 
4.4 Domestic Companies Retain Leadership in the Chinese Market but
 Multinational Pharma is Catching Up 
4.4.1 Visiongain Forecasts Strong Sales for Both Domestic and Foreign
 Pharma Companies in China from 2007-2020 
4.4.2 Gradual Change in Balance of Sales Contributed by Domestic and
 Foreign Companies in the Chinese Pharma Market from 2007-2020 
4.4.3 Chinese Pharmaceutical Industry Lags Behind Other Major
 Domestic Industries as well as the Indian Pharma Sector 
4.4.4 Domestic Producers Can Affect Pricing Structures in Chinese 
 Pharma Market 
4.4.5 Supply Chain Advantages for Domestic Producers 
4.4.6 Most Pharma Companies Located in the Dynamic Eastern and South
 China Zones 
4.5 Forecasts for Leading Therapeutic Classes in the Chinese
 Pharmaceutical Market from 2007-2013 
4.5.1 Leading Drug Classes in China will Show Marked Growth from
 2007-2023 
4.5.2 Growing Opportunities in Many Areas Including both Traditional
 Ailments and Modern Western-Style Diseases 
4.6 Forecasts for Leading Companies in the Chinese Pharmaceutical
 Market from 2007-2013 
4.6.1 Leading Companies both Domestic and Foreign Will Exhibit Strong
 Sales Growth from 2007-2023 
4.6.2 Bayer - A Potential Leader of the Chinese Pharma Market? 
4.7 The Pharmaceutical Market in China will be Driven by the Especially
 Strong Performance of the Chinese Economy from 2007 to 2020 
4.7.1 Historic Economic Progress Makes China Ready for a Healthcare
 Revolution 
4.7.2 Greater Inclusion in Public Healthcare Coverage will Constitute a
 Win-Win for Healthcare Stakeholders in China 
4.8 Political and Economic Reform Has Led to a Burgeoning Private
 Sector - International Pharmaceutical Companies Have Already
 Established Themselves in China 
4.8.1 Great Reforms in China Since 1978 
4.8.2 Improvement of Private Industry and Financial Sector Remains a
 Challenge 
4.8.3 Visiongain is Confident of Increasing Foreign Involvement in
 Chinese Pharma Sector - a Win-Win Situation for Companies and
 Other Stakeholders 
4.9 Mandatory Pricing Reductions Cause the International Pharma Industry
 Concern 
4.9.1 The National Reform and Development Commission 
4.9.2 Recent Price Cuts in Key Classes in China 
4.9.3 Reform of NRDC Policies and Processes May Bring Some Relief for
 Industry 
4.9.4 The Centralised Tendering System Has an Effect on Pharmaceutical
 Revenues 
4.10 Pharmaceuticals are a Major Source of Revenue Generation in Chinese
 Hospital System - Pharma Companies Need to Focus on those Powerful Buyers 
4.10.1 Hospital Pharmacies are Principal Dispensers of Drugs in China 
4.10.2 National Reimbursement Bulletin Guides Specific Formularies 
4.10.3 Anti-Corruption Campaign in 2006 had Implications for Prescribing
 Practices 
4.10.4 Proposals to Limit Drug Mark-Ups in Hospitals and Some Price Rises
 at Source 
4.10.5 Funding Situation in Hospitals will Improve - Healthcare
 Stakeholders will Benefit 
4.11 Developments in Intellectual Property in China Remain Vitally
 Important to the Global Pharma Industry 
4.11.1 Counterfeiting and Related Patent Incursions are Still
 Problematical in China 
4.11.2 Protection of Intellectual Property is Gradually Improving in
 China but Serious Concerns Remain 
4.11.3 Many Sales of Counterfeits and Illegal Generics Occur via the
 Internet 
4.11.4 Pfizer Recently Initiated an Anti-Counterfeiting Programme in
 Shanghai 
4.11.5 The Chinese Authorities Are Tightening Regulations and
 Enforcement 
4.12 Pharma Distribution Channels in China are Evolving 
4.12.1 Key Players Control Distribution 
4.12.2 Sole Authorized Agents 
4.12.3 The Market Network System 
4.12.4 A More Direct and Independent System 
4.12.5 E-Business and Retailing Chain Stores Show Potential 
4.13 Visiongain Concludes that China is the Largest and Most
 Attractive Developing Market for Pharmaceuticals 
5 Domestic Companies with Strong Promise for the Future Especially in
 Original Drug Development 
5.1 Original R&D Investment Lacking to Date but High Expectations from
 Chinese Government for Future 
5.1.1 Visiongain Believes that China Will Make Important Progress in
 Developing Novel Drugs for International Markets 
5.1.2 Relatively Low Investment in R&D is Still a Major Limitation 
5.1.3 Bio-scientific Knowledge and Skills Increasing Rapidly 
5.1.4 Pre-clinical and Clinical Trial Activities Emerging Rapidly 
5.1.5 The Chinese Pharmaceutical Industry and the Domestic Market
 have Noteworthy Characteristics 
5.1.6 Xiangxue Pharmaceuticals to Extend into UK 
5.2 Significant Changes to Regulatory Processes Occurred During 2007 
5.2.1 Changes to the Administration of Drug Regulation 
5.2.2 New Drug Registration Procedures Now Far More Discerning 
5.2.3 Improved Transparency and Speed of Regulatory Processes 
5.2.4 Special Approval Procedures for APIs, Biologicals and Some Chemical
 Agents 
5.3 Harbin Pharmaceutical Group 
5.3.1 Harbin Pharmaceutical Group is a Leading Antimicrobial Producer
 in China 
5.3.2 Antimicrobial Agents - a Speciality 
5.3.3 Foreign Investment in Harbin 
5.3.4 Novel R&D Activities 
5.3.5 Active Pharmaceutical Ingredients (APIs) 
5.3.6 Branded Products 
5.3.7 Generic Products 
5.4 Shijiazhuang Pharma Group 
5.4.1 Shijiazhuang Pharma Group is a Leading State-Owned Pharma Company 
5.4.2 Original R&D by Shijiazhuang Pharma Group 
5.4.3 Key Competencies of Shijiazhuang Pharma Group 
5.4.4 Subsidiaries and Affiliations 
5.5 Sinovac Biotech Ltd 
5.5.1 Sinovac Biotech is a Prominent Chinese Biotechnology Company and
 a Leader in Vaccines 
5.5.2 Sinovac Reported Impressive Sales and Profit Growth in 2006 
5.5.3 Bilive - the First Combined Inactivated Hepatitis A&B Vaccine 
5.5.4 Healive - an Inactivated Hepatitis A Vaccine 
5.5.5 Anflu - a Split Influenza Vaccine 
5.5.6 Pipeline Developments in Sinovac Biotech 
5.5.7 Sinovac Announced $9.75m Private Placement in Early 2008 
5.6 WuXi PharmaTech 
5.6.1 WuXi PharmaTech is an Exciting Pharma R&D Outsourcing Company 
5.6.2 WuXi PharmaTech - a Leading International Pharma Services Company
 of the Future? 
5.7 Interview with the Director of an Expanding Chinese Pharmaceutical
 Company 
5.7.1 The Greatest Challenges facing the Chinese Pharma Sector 
5.7.2 Growth Potential of Chinese Pharma Market 
5.7.3 China and IP Protection 
5.7.4 Development of Novel Pharmaceuticals in China 
5.7.5 Pricing Trends in the Chinese Market - 2008 Onwards 
5.7.6 Composition of Pharma Sales in China 
5.7.7 Public Healthcare Spending from 2008 Onwards 
5.7.8 Multinational Companies vs. Domestic Companies 
5.7.9 Development of the Wholesale and Distribution System 
5.7.10 Governmental Support for Chinese Pharma 
5.7.11 Inward Investment in the Chinese Pharma Sector 
5.8 China Has Expanding Role in Biologics and Biogenerics (Biosimilars) 
5.8.1 China Has Established Biogenerics Companies 
5.8.2 Emerging FDA and EMEA Policy for Biogenerics Creates Great
 Opportunities for Indian and Chinese Biotechnological Companies 
5.8.3 China Will Compete Internationally in Biogenerics and Eventually
 Original Biologics 
6 The Clinical Trials Outsourcing Market in China 
6.1 The Clinical Trials Markets in China Will Increase Steadily from
 2007-2023 
6.1.1 China Has Growing Presence in Clinical Outsourcing but Lags
 Behind India 
6.1.2 Chinese Clinical Outsourcing will Expand Steadily from 2007 to 2023 
6.1.3 Lack of Harmonisation a Challenge 
6.2 Many Factors are Considered When Deciding Clinical Trial Location
 but Quality of Data Should Be Paramount 
6.2.1 Both China and India are Attractive Locations for Clinical Trials 
6.2.2 The Quality Issue and Other Operational Factors 
6.3 China Faces Real Challenges to Establish Itself in the Clinical
 Trials Market 
6.3.1 China's Large Treatment-Naïve Population Is Attracting Investment
 but Healthcare Infrastructure Needs to Be Enhanced 
6.3.2 Multinational CROs have also Moved into China 
6.3.3 Rapid Growth of the Pharmaceutical Market Will Drive Clinical
 Research in China 
6.3.4 Enforcement of Intellectual Property Law Is the Most Pressing Issue
 for China 
6.3.5 Lack of Clinical Trial Standardisation Will Also Inhibit Growth 
6.3.6 China Will Take Some Time to Fulfil its Potential in this Sector 
6.4 The Drive for Patient Recruitment has Pushed Clinical Trials East 
6.4.1 Speed and Cost in Clinical Development 
6.4.2 Advantages of Outsourcing Clinical Trials in China 
6.4.3 Disadvantages of Outsourcing Clinical Trials in China 
6.4.4 Costs of Clinical Testing in China will Not Remain Low Forever 
6.4.5 Exciting Prospects in China: Where Optimism and Caution Meet 
7 Outsourced Pharmaceutical Manufacturing in China 
7.1 Low-Cost Manufacturing in China is Very Attractive to International
 Pharmaceutical Companies 
7.1.1 Expanding Contract Pharma Markets in China - APIs in Particular 
7.1.2 Outsourcing to China as a Tactical Decision 
7.1.3 FDA Approval and GMP in China 
7.2 Drivers and Restraints on Outsourced Pharma Manufacturing in China 
7.2.1 TRIPs and Other Regulations Affect China in Particular 
7.2.2 Not all International Companies Believe that Outsourced Pharma
 Manufacture in China is Desirable 
7.2.3 How International GMP Standards Will Affect the Chinese Pharma
 Industry 
7.3 The Importance of APIs to Chinese Sector: Opportunities and
 Challenges 
7.3.1 Increasing Competition and Commoditisation - Especially in Bulk
 Pharma Manufacturing 
7.3.2 Biotechnological Capacity in China from the Present Looking Forward 
7.3.3 Overcoming the Challenges of this Transitional Period in Pharma
 Manufacturing 
7.4 China's Role in API Production and Export Will Grow Significantly in
 the Years Ahead 
7.4.1 Chinese Exports of APIs Will Exceed $15bn by 2013 with Further
 Growth Predicted 
7.4.2 China Will Prosper in API Production at the Expense of Traditional
 European Producers 
7.4.3 While China is an Expanding Producer of APIs, India is a Serious
 Rival - Who Will Win During Coming Years? 
7.4.4 European API Producers Set to Lose Market Share to China 
7.4.5 Shares by Class and Costs by Volume 
7.4.6 Geographical Distribution of Chinese Pharma Exports 
7.4.7 China is Also an Important Producer of Pharmaceutical
 Intermediaries 
8 Pharmaceutical Joint Ventures 
8.1 International Joint Ventures in Chinese Healthcare 
8.1.1 An Important Driver of Pharmaceutical Market Growth 
8.1.2 Incentives to Foreign Investment in the Chinese Pharma Sector 
8.1.3 Characteristics of Healthcare Joint Ventures (JVs) 
8.1.4 Joint Ventures an Established Strategy 
8.2 Important Healthcare Policy Regulates Joint Ventures 
8.2.1 Entry Criteria for Companies 
8.2.2 Chinese-Foreign Equity Joint Venture Law 
8.2.3 Technology Transfer and its Regulation 
8.2.4 Economic Zones and Chinese Industrial Policy 
8.3 State Owned Enterprises (SOEs) 
8.3.1 SOEs are a Salient Characteristic of the Chinese Pharma Sector 
8.3.2 Healthcare (Hospital) Joint Ventures in China 
8.3.3 Provisional Regulations on the Administration of Healthcare
 Joint Ventures 
8.3.4 MPOH and MOFTEC Requirements Affect Market Participants 
8.4 Research and Development 
8.4.1 China is Making Only Gradual Progress in Mobilising its Public
 Sector Science and Engineering 
8.4.2 ROI in State Research Remains Low 
8.4.3 IP Issues as Restraints to Progress in Basic Healthcare Science 
9 Conclusions 
9.1 The Chinese Pharmaceutical Market Will Expand to over $30bn by
 Early Next Decade with Strong Growth Continuing to 2020 
9.2 Sales of Prescription Drugs in China Set to Exceed $50bn by Late
 Next Decade with a CAGR over 15% 
9.3 Strong Growth in both Branded and Generic Sectors from 2007-2020 
9.4 Visiongain Forecasts Strong Sales for Both Domestic and Foreign
 Pharma Companies in China from 2007-2020 
9.5 There Will be a Gradual Change in Balance of Sales Contributed by
 Domestic and Foreign Companies in the Chinese Pharma Market from
 2007-2020 
9.6 The Leading Drug Classes in China will Show Marked Growth from
 2007-2023 
9.7 Demographic Changes a Major Driver of Pharmaceutical Sales 
9.8 Visiongain Concludes that China is the Largest and Most
 Attractive Developing Market for Pharmaceuticals 

Appendices 
Appendix A: The Chinese Pharma Regulatory System 
Appendix B: Healthcare Insurance in China 
Appendix C: Drug Pricing 
Appendix D: About Visiongain 
Appendix E: Visiongain Report Evaluation Form 
List of Tables 
Table 1.1 World Market and China: Long Range Sales Forecasts ($bn)
 with CAGR (%), 2007-2023 
Table 2.1 Total Sales ($bn) of the World Pharmaceutical Market,
 2000-2006 
Table 2.2 Forecast Sales ($bn) of the World Pharmaceutical Market,
 2007-2013 
Table 2.3 Forecast Sales ($bn) of the World Pharmaceutical Market,
 2014-2020 
Table 2.4 Major Drugs Losing Patent Expiry in Near Future 
Table 2.5 Top 20 Ranking Nations in the Global Pharmaceutical Market,
 2006 
Table 2.6 World Pharmaceutical Sales ($bn) by Region, 2005 
Table 2.7 Total Sales ($bn), Growth (%) and Market Share (%) for
 Leading Developing Markets, 2005 
Table 2.8 Combined Total Sales ($bn), Growth (%) and Market Share (%)
 for Leading Developing Markets by Region, 2005 
Table 2.9 The 10 Most Populous Countries - 2005 and 2030 Compared 
Table 3.1 A SWOT Analysis for the Chinese Pharmaceutical Market,
 2008-2023 
Table 3.2 China: Fundamental Demographics and Healthcare Economics,
 2006 
Table 3.3 Chinese Sales of Leading Companies in the Chinese
 Pharmaceutical Market by Sales ($m), 2006 
Table 3.4 Leading Domestic Companies in China by Sales ($m), 2006 
Table 3.5 Fastest Growing Domestic Companies in China by Sales ($m),
 2006 
Table 3.6 Leading Therapy Classes China, 2006 
Table 3.7 Fastest Growing Therapy Classes in China by Sales ($m), 2006 
Table 3.8 Leading Pharmaceutical Agents in China by Sales ($m), 2006 
Table 4.1 Total Pharmaceutical Sales ($bn) in China and the World
 Compared, 2007-2013 
Table 4.2 World Market and China: Long Range Sales Forecasts ($bn) with
 CAGR (%), 2007-2023 
Table 4.3 Total Pharmaceutical Sales ($bn) in China and the World
 Compared, 2014-2020 
Table 4.4 CAGR (%) for Pharmaceutical Sales in China and the Total World
 Market, 2007-2020 
Table 4.5 China's Share (%) of Total World Pharma Market Sales, 2007-2013 
Table 4.6 China's Share (%) of Total World Pharma Market Sales, 2014-2020 
Table 4.7 Total Sales ($bn) of Prescription and OTC Medicines in China,
 2007-2013 
Table 4.8 Total Sales ($bn) of Prescription and OTC Medicines in China,
 2014-2020 
Table 4.9 Prescription and OTC Medicines: Long Range Sales Forecasts ($bn)
 with CAGR (%), 2007-2023 
Table 4.10 CAGR (%) for Total Sales of Prescription and OTC Medicines in
 China 2007-2020 
Table 4.11 Market Shares (%) Held by Prescription and OTC Medicines in
 China, 2007-2013 
Table 4.12 Market Shares (%) Held by Prescription and OTC Medicines in
 China, 2014-2020 
Table 4.13 Total Sales ($bn) of Original Branded and Generic Prescription
 Drugs in China, 2007-2013 
Table 4.14 Total Sales ($bn) of Original Branded and Generic Prescription
 Drugs in China, 2014-2020 
Table 4.15 Branded and Generic Prescription Drugs: Long Range Sales
 Forecasts ($bn) with CAGR (%), 2007-2023 
Table 4.16 CAGR (%) for Total Sales of Original Branded and Generic
 Prescription Drugs in China, 2014-2020 
Table 4.17 Shares (%) of the Prescription Drug Market Held by Original
 Patented and Generic Prescription Drugs in China, 2007-2013 
Table 4.18 Shares (%) of the Prescription Drug Market Held by Original
 Patented and Generic Prescription Drugs in China, 2014-2020 
Table 4.19 Total Sales ($bn) of Domestic Pharma Companies and Foreign 
 Pharma in China, 2007-2013 
Table 4.20 Total Sales ($bn) of Domestic Pharma Companies and Foreign
 Pharma in China, 2014-2020 
Table 4.21 Domestic Pharma Companies and Foreign Pharma: Long Range
 Sales Forecasts ($bn) with CAGR (%), 2007-2023 
Table 4.22 CAGR (%) for Total Sales of Domestic Pharma Companies and
 Foreign Pharma in China, 2007-2020 
Table 4.23 Shares (%) of Chinese Pharma Market Held by Domestic Companies
 and Foreign Companies, 2007-2013 
Table 4.24 Shares (%) of Chinese Pharma Market Held by Domestic Companies
 and Foreign Companies, 2014-2020 
Table 4.25 Sales ($m) of Leading Therapy Classes in China, 2007-2013 
Table 4.26 Sales ($m) of Leading Therapy Classes in China, 2007-2013
 (Continued) 
Table 4.27 CAGR (%) for Sales of Leading Therapy Classes in China,
 2007-2013 
Table 4.28 Leading Therapy Classes: Long Range Sales Forecasts ($m) with
 CAGR (%), 2007-2023 
Table 4.29 Chinese Sales ($m) of Leading Companies in the Chinese
 Pharmaceutical Market, 2007-2013 
Table 4.30 Chinese Sales ($m) of Leading Companies in the Chinese
 Pharmaceutical Market, 2007-2013 (Continued) 
Table 4.31 CAGR (%) for Chinese Sales of Leading Companies in the Chinese
 Pharmaceutical Market, 2007-2013 
Table 4.32 Leading Companies: Long Range Sales Forecasts ($m) with CAGR
 (%), 2007-2023 
Table 6.1 Revenues ($bn) for Chinese Clinical Trials Sector, 2007-2013 
Table 6.2 Revenues ($bn) for Chinese Clinical Trials Sector, 2014-2020 
Table 6.3 Clinical Trials in China: Long Range Revenue Forecasts ($bn)
 with CAGR (%), 2007-2023 
Table 6.4 Disease Prevalence (m) in China, 2006 
Table 7.1 Revenues ($bn) for Chinese API Exports, 2007-2013 
Table 7.2 Revenues ($bn) for Chinese API Exports, 2014-2020 
Table 7.3 Chinese API Exports: Long Range Revenue Forecasts ($bn) with
 CAGR (%), 2007-2023 
Table 7.4 Leading Chinese Exported APIs, 2005 

List of Figures 
Figure 1.1 Total Pharmaceutical Sales ($bn) in China, 2007-2020 
Figure 2.1 Total Sales ($bn) of the World Pharmaceutical Market, 2000-2006 
Figure 2.2 Forecast Sales ($bn) of the World Pharmaceutical Market,
 2007-2020 
Figure 2.3 The Drug Development Process is Long, Complex and Costly 
Figure 3.1 Breakdown (%) of the Chinese Market ($bn) by Conventional
 Prescription Drugs, OTC Products and Traditional Chinese Medicines, 2005 
Figure 4.1 Total Pharmaceutical Sales ($bn) in China and the World
 Compared, 2007-2013 
Figure 4.2 Total Pharmaceutical Sales ($bn) in China, 2007-2013 
Figure 4.3 Total Pharmaceutical Sales ($bn) in China and the World
 Compared, 2014-2020 
Figure 4.4 Total Pharmaceutical Sales ($bn) in China, 2014-2020 
Figure 4.5 CAGR (%) for Pharmaceutical Sales in China and the Total
 World Market, 2007-2020 
Figure 4.6 China's Share (%) of Total World Pharma Market Sales,
 2007-2013 
Figure 4.7 China's Share of the World Pharmaceutical Market in 2007 
Figure 4.8 China's Share of the World Pharmaceutical Market in 2010 
Figure 4.9 Total Pharmaceutical Sales ($bn) in China and the World
 Compared, 2007-2013 
Figure 4.10 Growth of Total Sales in China and World Market Compared,
 2007-2013 
Figure 4.11 Growth in Pharmaceutical Sales in China, 2007-2013 
Figure 4.12 Rate of Growth (%) of Percentage Market Share for China
 in the Global Pharmaceutical Market, 2007-2013 
Figure 4.13 China's Share (%) of Total World Pharma Market Sales, 2014-2020 
Figure 4.14 China's Share of the World Pharmaceutical Market in 2014 
Figure 4.15 China's Share of the World Pharmaceutical Market in 2020 
Figure 4.16 Total Pharmaceutical Sales ($bn) in China and the World
 Compared, 2014-2020 
Figure 4.17 Growth of Total Sales China and World Market Compared,
 2014-2020 
Figure 4.18 Growth in Pharmaceutical Sales in China, 2014-2020 
Figure 4.19 Rate of Growth (%) of Percentage Market Share for China
 in the Global Pharmaceutical Market, 2014-2020 
Figure 4.20 Total Sales ($bn) of Prescription and OTC Medicines in China,
 2007-2013 
Figure 4.21 Total Sales ($bn) of Prescription and OTC Medicines in China,
 2014-2020 
Figure 4.22 CAGR (%) for Total Sales of Prescription and OTC Medicines in
 China 2007-2020 
Figure 4.23 Market Shares (%) Held by Prescription and OTC Medicines in
 China, 2007-2013 
Figure 4.24 Market Shares (%) Held by Prescription and OTC Medicines in
 China, 2014-2020 
Figure 4.25 Total Sales ($bn) of Original Branded and Generic Prescription
 Drugs in China, 2007-2013 
Figure 4.26 Total Sales ($bn) of Original Branded and Generic Prescription
 Drugs in China, 2014-2020 
Figure 4.27 Total Sales of Original Branded and Generic Prescription Drugs
 in China CAGR (%), 2014-2020 
Figure 4.28 Shares (%) of the Prescription Drug Market Held by Original
 Patented and Generic Prescription Drugs in China, 2007-2013 
Figure 4.29 Shares (%) of the Prescription Drug Market Held by Original
 Patented and Generic Prescription Drugs in China, 2014-2020 
Figure 4.30 Total Sales ($bn) of Domestic Pharma Companies and Foreign
 Pharma in China, 2007-2013 
Figure 4.31 Total Sales ($bn) of Domestic Pharma Companies and Foreign
 Pharma in China, 2014-2020 
Figure 4.32 Total CAGR (%) for Total Sales of Domestic Pharma Companies
 and Foreign Pharma in China, 2007-2020 
Figure 4.33 Shares (%) of Chinese Pharma Market Held by Domestic Companies
 and Foreign Companies, 2007-2013 
Figure 4.34 Shares (%) of Chinese Pharma Market Held by Domestic Companies
 and Foreign Companies, 2014-2020 
Figure 4.35 Sales ($m) of Leading Therapy Classes in China, 2006-2013 
Figure 4.36 Sales ($m) of Leading Therapy Classes in China, 2006-2013
 (Continued) 
Figure 4.37 Chinese Sales ($m) of Leading Companies in the Chinese
 Pharmaceutical Market, 2006-2013 
Figure 4.38 Chinese Sales ($m) of Leading Companies in the Chinese
 Pharmaceutical Market, 2006-2013 (Continued) 
Figure 6.1 Revenues ($bn) for Chinese Clinical Trials Sector, 2007-2020 
Figure 6.2 Factors Affecting Clinical Trial Location 
Figure 7.1 Revenues ($bn) for Chinese API Exports, 2007-2020 
Figure 7.2 Market Share (%) of the Chinese API Market by Class, 2005 
Figure 7.3 Global Distribution of Chinese API Exports, 2005



More Details

Companies Mentioned in this Report 
Anhui Anke Biotechnology 
Anhui BBCA Biochemical 
AppTec Laboratory Services 
AstraZeneca 
Aventis Pharma 
Bayer AG 
Bayer Schering Pharma Asia Pacific 
Beijing SL Pharmaceutical 
Beijing Tiantan Biological Products 
Beijing Tri-Prime Genetic Engineering 
Bristol Myers Squibb 
Changchun ChangSheng Gene 
Changchun Institute of Biological Products 
Chengdu Rongsheng Pharmaceuticals 
China National Biotec Corp (CBNC) 
China Pharmaceutical Group 
Cipla 
Citic Capital 
Danish Centre for Clinical and Basic Research 
Dr. Reddy's Laboratories 
Eli Lilly 
Fresenius 
GlaxoSmithKline 
Guangxi Beisheng Pharmaceuticals 
Hainan Sanyang Pharma 
Hangzhou Jiuyuan Gene Engineering 
Harbin Pharmaceutical Group 
Hebei Zhongrun Pharmaceutical Co 
HLJ Haerbin Pharma 
Hualan Biological Engineering 
Huawei 
Jiangsu YangZijiang Js. LYG Hengrui 
Johnson & Johnson 
Jx.Nanchang Yufeng 
Lenovo 
M.S.D.-Hangzhou 
MDS Pharma Services 
Microsoft 
Motorola 
NCPC Genetech Biotechnology 
Shanghai Institute of Biological Products 
Northeast General Pharmaceutical Factory 
Novartis 
Novo Nordisk 
Pfizer 
Quintiles 
Ranbaxy 
Roche 
Roche-Shanghai 
Sandoz 
Sanofi-Aventis 
Sanofi-Syn.M-Sheng 
Sansar Capital Management 
Sh.Asia Pioneer Pharma 
Shadong XINHUA Pharma 
Shandong Luoxin Pharma 
Shandong Qilu Fty 
Shanghai-Squibb 
Shenyang Sunshine Pharma 
Shenzhen Kexing Biotech 
Shenzhen Xinlitai 
Shijiazhuang Pharma Group 
Sichuan Kelun Pharma 
Sinovac Biotech 
Teva 
Th.James-Andy 
Tianjin Hualida Biotechnology 
Tianjin Smith Kline & Beecham 
Warburg Pincus 
Weisheng Pharmaceutical (Shijiazhuang) Co 
WuXi PharmaTech 
Wyeth 
Xiamen Amoytop Biotech 
Xian Janssen 
Xiangxue Pharmaceuticals 
Zhejiang Medicine 
Zhejiang NHU

To order this report:

Chinese Pharmaceutical Outlook 2008-2023

http://www.reportlinker.com/p090279/Chinese-Pharmaceutical-Outlook-2008-2023.html

More market research reports here!

Contact Information